Title
Elevated circulating concentrations of interferon-gamma in latent tuberculosis infection
Date Issued
01 November 2016
Access level
open access
Resource Type
journal article
Author(s)
Deepe G.S.
Fichtenbaum C.J.
Universidad de Cincinnati
Publisher(s)
Case Western Reserve University
Abstract
Background: Latent tuberculosis infection (LTBI) has been associated with increased immune activation. We assessed circulating concentrations of interferon-gamma in persons with LTBI. Methods: We used the 2011-2012 National Health Nutritional Examination Survey (NHANES) to identify adults with and without LTBI by QuantiFERON®-TB Gold In-Tube (QFT) results. Non-LTBI persons were 1:1 age-, gender-, and race-matched to LTBI persons using propensity scores. We compared the plasma concentrations of interferon-gamma measured from the unstim-ulated, negative control QFT tube between LTBI and non-LTBI persons. We used Mann-Whitney tests and ordered logistic regressions for comparisons. Results: There were 430 LTBI and 430 non-LTBI matched persons included in the analysis. LTBI was associated with higher circulating concentrations of interferon-gamma (median, 3 pg/mL; IQR, 2 – 5) compared to non-LTBI (median, 2.5 pg/mL; IQR, 1.5 – 3.5); P < 0.001. LTBI remained associated with higher interferon-gamma concentrations after adjusting for age, gender, race, diabetes, hypertension, tobacco use, HIV status, body mass index, lipid profile, and lympho-cyte count (odds ratio, 1.79, 95% CI, 1.26 – 2.53). Results remained similar when tuberculin skin testing defined LTBI. Conclusions: LTBI was associated with increased circulating interferon-gamma concentrations. Future studies are needed to further characterize immune activation in LTBI and its potential long-term consequences.
Start page
291
End page
303
Volume
1
Issue
2
Language
English
OCDE Knowledge area
Inmunología Enfermedades infecciosas
Scopus EID
2-s2.0-85018225696
Source
Pathogens and Immunity
ISSN of the container
2469-2964
Sponsor(s)
Support was provided, in part, for Dr. Fichtenbaum from the National Institute of Allergy and Infectious Diseases (NIAID), through AIDS Clinical Trials Group Grant UM1-AI 69439; and for Dr. Huaman from the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant UL-1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Sources of information: Directorio de Producción Científica Scopus